Update on Inflammation, Aging, and CMV Co-Infection in Treated HIV

Peter W. Hunt, MD
Professor of Medicine, Division of Experimental Medicine, UCSF
Co-Director of Basic/Translational Sciences, Center for AIDS Research
San Francisco, CA

CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenter:Top of page

Peter Hunt’s primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand the causes and consequences of persistent immune activation and its impact on aging-associated multi-morbidity and mortality in treated HIV infection, as well as its impact on HIV persistence. He also conducts clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group (ACTG). In July 2016, he also started a laboratory to better characterize the immune defects that drive morbidity and mortality in treated HIV, with a specific focus on the role of CMV co-infection as an important mediator. He leads a large clinical trial of the anti-CMV drug letermovir in the ACTG, exploring its impact not just on systemic inflammation, but also on cardiometabolic and neurocognitive outcomes. Dr. Hunt led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection.

Learning Objectives: Top of page

At the completion of this educational session, learners will:
1. Be aware of the causes and putative consequences of persistent inflammation in treated HIV.
2. Know the current strategies being pursued to decrease immune activation and multimorbidity in treated HIV.
3. Understand the evidence suggesting that CMV may play an important role in multimorbidity in treated HIV as well as COVID-19 complications.

CME Information:Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for April 12, 2023, as a live activity. This activity will also be available as an enduring activity from April 19, 2023, through April 11, 2026.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director/Planner) has no relevant financial relationships to disclose.
- Dr. Keith A. LaScalea (Moderator) has no relevant financial relationships to disclose.
- Dr. Peter W. Hunt (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to: Merck, ViiV and Biotron; Drug donation for trial from: Merck; Research grant from: Gilead; Honoraria from: ViiV and Gilead. Dr. Hunt submitted his slides in advance for adequate peer review and supported his presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships were mitigated.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register